Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Search

Page Path
HOME > Search
4 "Ho Sup Lee"
Filter
Filter
Article category
Keywords
Publication year
Authors
Original Articles
Treatment Outcomes of Rituximab Plus Hyper-CVAD in Korean Patients with Sporadic Burkitt or Burkitt-like Lymphoma: Results of a Multicenter Analysis
Junshik Hong, Seok Jin Kim, Jae-Sook Ahn, Moo Kon Song, Yu Ri Kim, Ho Sup Lee, Ho-Young Yhim, Dok Hyun Yoon, Min Kyoung Kim, Sung Yong Oh, Yong Park, Yeung-Chul Mun, Young Rok Do, Hun-Mo Ryoo, Je-Jung Lee, Jae Hoon Lee, Won Seog Kim, Cheolwon Suh
Cancer Res Treat. 2015;47(2):173-181.   Published online October 28, 2014
DOI: https://doi.org/10.4143/crt.2014.055
AbstractAbstract PDFPubReaderePub
Purpose
This study was conducted to evaluate outcomes in adult patients with Burkitt lymphoma (BL) or Burkitt-like lymphoma treated with an rituximab plus hyper-CVAD (R-hyper-CVAD) regimen by focusing on tolerability and actual delivered relative dose intensity (RDI).
Materials and Methods
Patients ≥ 20 years of age and pathologically diagnosed with BL or Burkitt-like lymphoma were treated with at least one cycle of R-hyper-CVAD as the first-line treatment in this study. Eligible patients’ case report forms were requested from their physicians to obtain clinical and laboratory data for this retrospective study.
Results
Forty-three patients (median age, 51 years) from 14 medical centers in Korea were analyzed, none of which were infected with human immunodeficiency virus. The majority of patients had advanced diseases, and 24 patients achieved a complete response (75.0%). After a median follow-up period of 20.0 months, 2-year event-free and overall survival rates were 70.9% and 81.4%, respectively. Eleven patients (25.6%) were unable to complete the R-hyper-CVAD regimen, including six patients due to early death. The RDIs of adriamycin, vincristine, methotrexate, and cytarabine were between 60% and 65%, which means less than 25% of patients received greater than 80% of the planned dose of each drug. Poor performance status was related to the lower RDIs of doxorubicin and methotrexate.
Conclusion
R-hyper-CVAD showed excellent treatment outcomes in patients who were suitable for dose-intense chemotherapy. However, management of patients who are intolerant to a dose-intense regimen remains problematic due to the frequent occurrence of treatmentrelated complications.

Citations

Citations to this article as recorded by  
  • Comparison of chemotherapy regimens plus rituximab in adult Burkitt lymphoma: A single-arm meta-analysis
    Xiaoxuan Lu, Yu Liu, Ruyu Liu, Jiaxin Liu, Xiaojing Yan, Liren Qian
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Trends in survival of patients with stage I/II Burkitt lymphoma in the United States: A SEER database analysis
    Ze‐Long Liu, Pan‐Pan Liu, Xi‐Wen Bi, De‐Xin Lei, Yu Wang, Zhi‐Ming Li, Wen‐Qi Jiang, Yi Xia
    Cancer Medicine.2019; 8(3): 874.     CrossRef
  • ERK-dependent IL-6 positive feedback loop mediates resistance against a combined treatment using danusertib and BKM120 in Burkitt lymphoma cell lines
    Jun Liu, Junshik Hong, Kwang-Sung Ahn, Junhyeok Go, Heejoo Han, Jihyun Park, Dongchan Kim, Hyejoo Park, Youngil Koh, Dong-Yeop Shin, Sung-Soo Yoon
    Leukemia & Lymphoma.2019; 60(10): 2532.     CrossRef
  • Lymphoma epidemiology in Korea and the real clinical field including the Consortium for Improving Survival of Lymphoma (CISL) trial
    Kwai Han Yoo, Hyewon Lee, Cheolwon Suh
    International Journal of Hematology.2018; 107(4): 395.     CrossRef
  • Recent advances in treating extra-ocular lymphomas
    Lauge Hjorth Mikkelsen, Natacha Storm Würtz, Steffen Heegaard
    Expert Review of Ophthalmology.2018; 13(4): 205.     CrossRef
  • The Consortium for Improving Survival of Lymphoma (CISL): recent achievements and future perspective
    Cheolwon Suh, Byeong-Bae Park, Won Seog Kim
    Blood Research.2017; 52(1): 3.     CrossRef
  • Primary lymphomas in the gastrointestinal tract
    Jiang Chen Peng, Lu Zhong, Zhi Hua Ran
    Journal of Digestive Diseases.2015; 16(4): 169.     CrossRef
  • 15,627 View
  • 142 Download
  • 10 Web of Science
  • 7 Crossref
Close layer
Clinical Usefulness of Hydromorphone-OROS in Improving Sleep Disturbances in Korean Cancer Patients: A Multicenter, Prospective, Open-Label Study
Seong Hoon Shin, Ho Sup Lee, Yang Soo Kim, Young Jin Choi, Sung Hyun Kim, Hyuk Chan Kwon, Sung Yong Oh, Jung Hun Kang, Chang Hak Sohn, Sang Min Lee, Jin Ho Baek, Young Joo Min, Choongrak Kim, Joo Seop Chung
Cancer Res Treat. 2014;46(4):331-338.   Published online July 21, 2014
DOI: https://doi.org/10.4143/crt.2013.130
AbstractAbstract PDFPubReaderePub
Purpose
To evaluate the efficacy of hydromorphone-OROS (HM-OROS) in reducing sleep disturbance and relieving cancer pain. Materials and Methods One hundred twenty cancer patients with pain (numeric rating scale [NRS] ≥ 4) and sleep disturbance (NRS ≥ 4) were evaluated. The initial HM-OROS dosing was based on previous opioid dose (HM-OROS:oral morphine=1:5). Dose adjustment of the study drug was permitted at the investigator’s discretion. Pain intensity, number of breakthrough pain episodes, and quality of sleep were evaluated. Results A total of 120 patients received at least one dose of HM-OROS; 74 of them completed the final assessment. Compared to the previous opioids, HM-OROS reduced the average pain NRS from 5.3 to 4.1 (p < 0.01), worst pain NRS from 6.7 to 5.4 (p < 0.01), sleep disturbance NRS from 5.9 to 4.1 (p < 0.01), incidence of breakthrough pain at night from 2.63 to 1.53 times (p < 0.001), and immediate-release opioids use for the management of breakthrough pain from 0.83 to 0.39 times per night (p = 0.001). Of the 74 patients who completed the treatment, 83.7% indicated that they preferred HM-OROS to the previous medication. The adverse events (AEs) were somnolence, asthenia, constipation, dizziness, and nausea. Conclusion HM-OROS was efficacious in reducing cancer pain and associated sleep disturbances. The AEs were manageable.

Citations

Citations to this article as recorded by  
  • Pain and Analgesic Related Insomnia
    Jana Mlíchová, Zoltán Paluch, Ondřej Šimandl
    Pain Management Nursing.2023; 24(3): 254.     CrossRef
  • Initial titration with 200 μg fentanyl buccal tablets: a retrospective safety analysis in Korean cancer patients
    Mi-Young Kwon, Ha-Na Cho, Dong-Hoe Koo, Yun-Gyoo Lee, Sukjoong Oh, Seung-Sei Lee
    The Korean Journal of Internal Medicine.2018; 33(3): 577.     CrossRef
  • Endogenous Opiates and Behavior: 2015
    Richard J. Bodnar
    Peptides.2017; 88: 126.     CrossRef
  • Drug Formulation Advances in Extended-Release Medications for Pain Control
    Mark R. Jones, Martin J. Carney, Rachel J. Kaye, Amit Prabhakar, Alan D. Kaye
    Current Pain and Headache Reports.2016;[Epub]     CrossRef
  • The Clinical Applications of Extended-Release Abuse-Deterrent Opioids
    Nalini Vadivelu, Erika Schermer, Gopal Kodumudi, Jack M. Berger
    CNS Drugs.2016; 30(7): 637.     CrossRef
  • Once-Daily OROS Hydromorphone for Management of Cancer Pain: an Open-Label, Multi-Center, Non-Interventional Study
    Cheol Kyu Park, Hyun-Wook Kang, In-Jae Oh, Young-Chul Kim, Yeo-Kyeoung Kim, Kook-Joo Na, Sung-Ja Ahn, Tae Ok Kim, Young Jin Choi, Geun Am Song, Min Ki Lee
    Journal of Korean Medical Science.2016; 31(12): 1914.     CrossRef
  • 13,036 View
  • 80 Download
  • 6 Crossref
Close layer
Case Report
Successful Chemotherapy Following Autologous Stem Cell Transplantation in Multiple Myeloma and Multi-organ Dysfunction with Infiltration of Eosinophils: A Case Report
Ho Sup Lee, Lee Chun Park, Seong Hoon Shin, Sang Uk Lee, Hee Kyung Chang, Bang Huh, Gyoo Sik Jung, Mi Hyang Kim, Yang Soo Kim
Cancer Res Treat. 2011;43(3):199-203.   Published online September 30, 2011
DOI: https://doi.org/10.4143/crt.2011.43.3.199
AbstractAbstract PDFPubReaderePub
Eosinophils are derived from hematopoietic stem cells. Peripheral blood eosinophilia is defined as an absolute eosinophil count of > or =0.5x10(9)/L. Eosinophilia is classified into primary or clonal eosinophilia, secondary eosinophilia, and idiopathic categories including idiopathic hypereosinophilic syndrome. Both hematopoietic and solid neoplasms may be associated with peripheral blood eosinophilia, but multiple myeloma is rarely associated with eosinophilia. We now report the case of a 31-year-old man with multiple myeloma associated with marked eosinophilia who developed multiple organ dysfunction with infiltration of eosinophils. He recovered after treatment with chemotherapy followed by autologous stem cell transplantation.

Citations

Citations to this article as recorded by  
  • Subepidermal Bullous Dermatosis Associated With IgA Multiple Myeloma
    Qiang Zhou, Hao Jiang, Kejian Zhu, Rui Han, Hao Cheng
    The American Journal of Dermatopathology.2013; 35(3): e49.     CrossRef
  • 11,481 View
  • 58 Download
  • 1 Crossref
Close layer
Original Article
Clinical Correlation between Brain Natriutetic Peptide and Anthracyclin-induced Cardiac Toxicity
Ho Sup Lee, Chang Bae Son, Seong Hoon Shin, Yang Soo Kim
Cancer Res Treat. 2008;40(3):121-126.   Published online September 30, 2008
DOI: https://doi.org/10.4143/crt.2008.40.3.121
AbstractAbstract PDFPubReaderePub
Purpose

Anthracycline can effectively treat hematologic malignancies, but has significant risk of cardiotoxicity. We measured the clinical correlation between brain natriuretic peptide (BNP) and anthracycline-induced cardiotoxicity.

Materials and Methods

Between March 2005 and March 2007, 86 patients with acute leukemia, malignant lymphoma, or multiple myeloma receiving systemic chemotherapy with anthracycline were enrolled in the Department of Hemato-oncology, Kosin University Gospel Hospital. We investigated the relationship between BNP level and cardiotoxicity through echocardiography, electrocardiography, BNP levels, and symptoms of heart failure at each chemotherapy cycle.

Results

Of the 86 participants (mean age, 48.5 years; range 20~65 years), cardiotoxicity developed in 21 patients (24.4%), with 2 patients showing arrhythmia only, 17 patients with transient aspects of heart failure, and 2 patients with chronic heart failure. Cardiotoxicity related to serum BNP level, age, cumulative dose of anthracycline, accompanying chronic disease, and elevated level of troponin-I. Heart failure was more common if BNP levels reached 100 pg/ml at least once.

Conclusions

The clinical correlation between BNP and cardiotoxicity was significant in patients with systemic anthracycline chemotherapy. A prospective clinical trial will be needed to identify the causal relationship between serum BNP level and cardiotoxicity.

Citations

Citations to this article as recorded by  
  • Comparison of the Efficacy, Safety, and Quality of Life of Pegylated Liposomal Doxorubicin-Cyclophosphamide versus Epirubicin-Cyclophosphamide in Patients with Early-Stage HER2-Negative Breast Cancer: A Prospective, Randomized, Multicenter, Phase II Study
    Ling-Ming Tseng, Fang Ming Chen, Shou-Tung Chen, Fiona Tsui-Fen Cheng, Tsu-Yi Chao, Ming-Shen Dai, Woei-Yau Kao, Ming-Hsin Yeh, Dar-Ren Chen, Liang-Chih Liu, Hewi Chung Wang, Hong-Tai Chang, Being Whey Wang, Jyh-Cherng Yu, Shin Cheh Chen, Guo-Shiou Liao,
    Oncology Research and Treatment.2024; 47(10): 484.     CrossRef
  • Low-Dose Radiation Reduces Doxorubicin-Induced Myocardial Injury Through Mitochondrial Pathways
    Di Zhao, Xin Jiang, Xinxin Meng, Dandan Liu, Yanwei Du, Lijing Zhao, Hongyu Jiang
    Dose-Response.2023;[Epub]     CrossRef
  • Electrocardiographic and biochemical analysis of anthracycline induced cardiotoxicity in breast cancer patients from Southern Sri Lanka
    Jayasinghe Arachchige Nirosha Sandamali, Ruwani Punyakanthi Hewawasam, Madappuli Arachchige Chaminda Sri S Fernando, Kamani Ayoma Perera Wijewardana Jayatilaka
    BMC Cancer.2023;[Epub]     CrossRef
  • Non-coding RNAs, cancer treatment and cardiotoxicity: A triad of new hope
    Rishabh Mittal, Sarath Krishnan M P, Rahul Saxena, Ananyan Sampath, Bela Goyal
    Cancer Treatment and Research Communications.2023; 36: 100750.     CrossRef
  • Cardiac Biomarkers for the Detection and Management of Cancer Therapy-Related Cardiovascular Toxicity
    Xinxin Zhang, Yuxi Sun, Yanli Zhang, Fengqi Fang, Jiwei Liu, Yunlong Xia, Ying Liu
    Journal of Cardiovascular Development and Disease.2022; 9(11): 372.     CrossRef
  • Genetic Polymorphisms Affecting Cardiac Biomarker Concentrations in Children with Cancer: an Analysis from the “European Paediatric Oncology Off-patents Medicines Consortium” (EPOC) Trial
    Farina Hellmann, Swantje Völler, Miriam Krischke, David Jamieson, Nicolas André, Gianni Bisogno, Alan Boddy, Georg Hempel
    European Journal of Drug Metabolism and Pharmacokinetics.2020; 45(3): 413.     CrossRef
  • Cardiotoxicity of Anthracyclines
    Daniela Cardinale, Fabiani Iacopo, Carlo Maria Cipolla
    Frontiers in Cardiovascular Medicine.2020;[Epub]     CrossRef
  • The Role of Biomarkers in Cardio-Oncology
    Kajaluxy Ananthan, Alexander R. Lyon
    Journal of Cardiovascular Translational Research.2020; 13(3): 431.     CrossRef
  • Cardiotoxicity - the first cause of morbidity and mortality in pediatric patients survivors of acute lymphoblastic leukemia
    Letitia Elena Radu, Roxana Corina Sfetea, Constantin Virgiliu Arion, Anca Colita
    Revista Romana de Medicina de Laborator.2020; 28(2): 133.     CrossRef
  • Oncologic therapies associated with cardiac toxicities: how to minimize the risks
    Daniela Cardinale, Federica Stivala, Carlo M. Cipolla
    Expert Review of Anticancer Therapy.2019; 19(5): 359.     CrossRef
  • Biomarkers in cancer therapy related cardiac dysfunction (CTRCD)
    Rohit Moudgil, Parag A. Parekh
    Heart Failure Reviews.2018; 23(2): 255.     CrossRef
  • Rutin Attenuates Carfilzomib-Induced Cardiotoxicity Through Inhibition of NF-κB, Hypertrophic Gene Expression and Oxidative Stress
    Faisal Imam, Naif O. Al-Harbi, Mohammed M. Al-Harbia, Hesham M. Korashy, Mushtaq Ahmad Ansari, Mohamed M. Sayed-Ahmed, Mahmoud N. Nagi, Muzaffar Iqbal, Md. Khalid Anwer, Imran Kazmi, Muhammad Afzal, Saleh Bahashwan
    Cardiovascular Toxicology.2017; 17(1): 58.     CrossRef
  • Using biomarkers to predict and to prevent cardiotoxicity of cancer therapy
    Daniela Cardinale, Gina Biasillo, Michela Salvatici, Maria Teresa Sandri, Carlo Maria Cipolla
    Expert Review of Molecular Diagnostics.2017; 17(3): 245.     CrossRef
  • Alternative Biomarkers for Combined Biology
    Yong-Hyun Kim, Jennifer Kirsop, Wai Hong Wilson Tang
    Heart Failure Clinics.2017; 13(2): 381.     CrossRef
  • Cardio-oncology: Gaps in Knowledge, Goals, Advances, and Educational Efforts
    Gina Biasillo, Carlo M. Cipolla, Daniela Cardinale
    Current Oncology Reports.2017;[Epub]     CrossRef
  • Cardiovascular Complications of Cancer Therapy
    Hui-Ming Chang, Rohit Moudgil, Tiziano Scarabelli, Tochukwu M. Okwuosa, Edward T.H. Yeh
    Journal of the American College of Cardiology.2017; 70(20): 2536.     CrossRef
  • Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management
    Giuseppe Curigliano, Daniela Cardinale, Susan Dent, Carmen Criscitiello, Olexiy Aseyev, Daniel Lenihan, Carlo Maria Cipolla
    CA: A Cancer Journal for Clinicians.2016; 66(4): 309.     CrossRef
  • Molecular mechanisms of cardiotoxicity of gefitinib in vivo and in vitro rat cardiomyocyte: Role of apoptosis and oxidative stress
    Hesham M. Korashy, Ibraheem M. Attafi, Mushtaq A. Ansari, Mohammed A. Assiri, Osamah M. Belali, Sheik F. Ahmad, Ibrahim A. AL-Alallah, Fawaz E.Al Anazi, Abdulqader A. Alhaider
    Toxicology Letters.2016; 252: 50.     CrossRef
  • Role of biomarkers in monitoring antiblastic cardiotoxicity
    Giuseppina Novo, Christian Cadeddu, Vincenzo Sucato, Pasquale Pagliaro, Silvio Romano, Carlo G. Tocchetti, Concetta Zito, Luca Longobardo, Savina Nodari, Maria Penco
    Journal of Cardiovascular Medicine.2016; 17: e27.     CrossRef
  • Biomarkers and Cancer Therapy-Related Cardiac Dysfunction
    Prateek Sharma, Mahin Rehman, Javed Butler, Michelle W. Bloom
    Current Cardiovascular Risk Reports.2016;[Epub]     CrossRef
  • The Role of Biomarkers in Decreasing Risk of Cardiac Toxicity after Cancer Therapy
    Christine Henri, Therese Heinonen, Jean-Claude Tardif
    Biomarkers in Cancer.2016; 8s2: BIC.S31798.     CrossRef
  • Serum B-type natriuretic peptide levels as a marker for anthracycline-induced cardiotoxicity
    YA-DI WANG, SU-XIAN CHEN, LI-QUN REN
    Oncology Letters.2016; 11(5): 3483.     CrossRef
  • Mitogen-Activated Protein Kinases Pathways Mediate the Sunitinib-Induced Hypertrophy in Rat Cardiomyocyte H9c2 Cells
    Hesham Mohamed Korashy, Hani A. Al-Suwayeh, Zaid H. Maayah, Mushtaq Ahmad Ansari, Sheikh Fayaz Ahmad, Saleh A. Bakheet
    Cardiovascular Toxicology.2015; 15(1): 41.     CrossRef
  • Cardiotoxicity due to Chemotherapy: the Role of Biomarkers
    Patrick L. Stevens, Daniel J. Lenihan
    Current Cardiology Reports.2015;[Epub]     CrossRef
  • Cardiac Complications of Chemotherapy: Role of Biomarkers
    Alessandro Colombo, Maria T. Sandri, Michela Salvatici, Carlo M. Cipolla, Daniela Cardinale
    Current Treatment Options in Cardiovascular Medicine.2014;[Epub]     CrossRef
  • Use of Biomarkers for the Assessment of Chemotherapy-induced Cardiac Toxicity
    Eric S. Christenson, Theodore James, Vineet Agrawal, Ben H. Park
    Clinical Biochemistry.2014;[Epub]     CrossRef
  • BNP Predicts Chemotherapy-Related Cardiotoxicity and Death: Comparison with Gated Equilibrium Radionuclide Ventriculography
    Dorthe Skovgaard, Philip Hasbak, Andreas Kjaer, Claudio Moretti
    PLoS ONE.2014; 9(5): e96736.     CrossRef
  • Using Cardiac Biomarkers and Treating Cardiotoxicity in Cancer
    Alessandro Colombo, Daniela Cardinale
    Future Cardiology.2013; 9(1): 105.     CrossRef
  • Exaggerated NT‐proBNP Production in Patients With Hematologic Malignancies: A Case Series
    Aileen Andreu, Maya Guglin
    Congestive Heart Failure.2012; 18(6): 333.     CrossRef
  • Evaluation of cardiac safety of lapatinib therapy for ErbB2-positive metastatic breast cancer: A single center experience
    Erkan Dogan, Hikmet Yorgun, Ibrahim Petekkaya, Necla Ozer, Kadri Altundag, Yavuz Ozisik
    Medical Oncology.2012; 29(5): 3232.     CrossRef
  • NT-ProBNP and cardiac troponin I in virulent canine babesiosis
    Remo Lobetti, Robert Kirberger, Ninette Keller, Frank Kettner, Eran Dvir
    Veterinary Parasitology.2012; 190(3-4): 333.     CrossRef
  • Approccio cardiologico al paziente sottoposto a trattamento antitumorale. Documento primo
    Lidia Boccardi, Daniela Cardinale, Maurizio Civelli, Chiara Lestuzzi, Carlo Materazzo, Nicola Maurea, Ines Monte, Stefano Oliva, Patrizia Piotti, Giuseppina Quattrocchi, Elisabetta Rossi, Giuseppe Toglia
    Journal of Cardiovascular Echography.2011; 21(1): 32.     CrossRef
  • Role of biomarkers in cardioncology
    Daniela Cardinale, Michela Salvatici, Maria T. Sandri
    Clinical Chemistry and Laboratory Medicine (CCLM).2011;[Epub]     CrossRef
  • Pharmacokinetics of doxorubicin after intratumoral injection using a thermosensitive hydrogel in tumor-bearing mice
    Ahmed M. Al-Abd, Ki-Yun Hong, Soo-Chang Song, Hyo-Jeong Kuh
    Journal of Controlled Release.2010; 142(1): 101.     CrossRef
  • Cardiac Involvement in Patients with Hematologic Malignancies
    Alessandro Allegra, Andrea Alonci, Sabina Russo, Antonino Cannavò, Giuseppa Penna, Arianna D'Angelo, Giacomo Bellomo, Caterina Musolino
    Journal of Investigative Medicine.2010; 58(7): 859.     CrossRef
  • 10,409 View
  • 80 Download
  • 35 Crossref
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP